CORCEPT THERAPEUTICS INC Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
CORCEPT THERAPEUTICS INC (CORT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $3.50M, a 133.33% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $1.50M, a 36.36% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $1.10M, a 42.11% decline from fiscal 2022.
- CORCEPT THERAPEUTICS INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $1.90M, a 35.71% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $3.50M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $1.50M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $1.10M 10-K · filed 2026-02-24 | |
| 2022-12-31 | $1.90M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $1.40M 10-K · filed 2024-02-15 | |
| 2020-12-31 | $200.00K 10-K · filed 2023-02-28 | |
| 2019-12-31 | $200.00K 10-K · filed 2022-02-15 | |
| 2018-12-31 | -$1.30M 10-K · filed 2021-02-23 | |
| 2017-12-31 | -$116.90M 10-K · filed 2020-02-24 | |
| 2016-12-31 | -$4.30M 10-K · filed 2019-02-26 | $4.30M 10-K · filed 2017-03-06 |
| 2015-12-31 | -$2.40M 10-K · filed 2018-02-28 | |
| 2014-12-31 | $15.90M 10-K · filed 2017-03-06 | |
| 2013-12-31 | $15.90M 10-K · filed 2016-03-10 | |
| 2012-12-31 | $14.00M 10-K · filed 2015-03-13 | |
| 2011-12-31 | $16.00M 10-K · filed 2014-03-14 | |
| 2010-12-31 | $13.50M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |